GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Central Pharmaceutical JSC No2 (HSTC:DP2) » Definitions » EBIT

Central Pharmaceutical JSC No2 (HSTC:DP2) EBIT : ₫ Mil (TTM As of . 20)


View and export this data going back to 2017. Start your Free Trial

What is Central Pharmaceutical JSC No2 EBIT?

Central Pharmaceutical JSC No2's earnings before interest and taxes (EBIT) for the six months ended in . 20 was ₫0.00 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

EBIT is also linked to Joel Greenblatt's definition of earnings yield.


Central Pharmaceutical JSC No2 EBIT Historical Data

The historical data trend for Central Pharmaceutical JSC No2's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Central Pharmaceutical JSC No2 EBIT Chart

Central Pharmaceutical JSC No2 Annual Data
Trend
EBIT

Central Pharmaceutical JSC No2 Semi-Annual Data
EBIT

Competitive Comparison of Central Pharmaceutical JSC No2's EBIT

For the Pharmaceutical Retailers subindustry, Central Pharmaceutical JSC No2's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Central Pharmaceutical JSC No2's EV-to-EBIT Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Central Pharmaceutical JSC No2's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Central Pharmaceutical JSC No2's EV-to-EBIT falls into.



Central Pharmaceutical JSC No2 EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

For stock reported annually, GuruFocus uses latest annual data as the TTM data. EBIT for the trailing twelve months (TTM) ended in . 20 was ₫ Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Central Pharmaceutical JSC No2  (HSTC:DP2) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Central Pharmaceutical JSC No2's annualized ROC % for the quarter that ended in . 20 is calculated as:

ROC % (Q: . 20 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: . 20 ) + Invested Capital (Q: . 20 ))/ count )
= * ( 1 - % )/( ( + )/ )
=/
= %

where

Note: The Operating Income data used here is one times the annual (. 20) data.

2. Joel Greenblatt's definition of Return on Capital:

Central Pharmaceutical JSC No2's annualized ROC (Joel Greenblatt) % for the quarter that ended in . 20 is calculated as:

ROC (Joel Greenblatt) %(Q: . 20 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: . 20  Q: . 20
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=/( ( ( + max(, 0)) + ( + max(, 0)) )/ )
=/( ( + )/ )
=/
= %

where Working Capital is:

Working Capital(Q: . 20 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=( + + ) - ( + + )
=

Working Capital(Q: . 20 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=( + + ) - ( + + )
=

When net working capital is negative, 0 is used.

Note: The EBIT data used here is one times the annual (. 20) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Central Pharmaceutical JSC No2's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: . 20 )
=/0.000
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Central Pharmaceutical JSC No2 EBIT Related Terms

Thank you for viewing the detailed overview of Central Pharmaceutical JSC No2's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Central Pharmaceutical JSC No2 (HSTC:DP2) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
No. 9 Tran Thanh Tong, Bach Dang Ward, Hai Ba Trung District, Hanoi, VNM
Central Pharmaceutical JSC No2 is engaged in the Trading of medicinal materials, pharmaceutical materials, chemicals, essential oils, modern medicines, traditional medicine drugs, cosmetics, and nutritious foods. Some of its products include Gentamycin injection solution 80; Genatreson Skin Cream; Ferimax Hard Capsules and others.

Central Pharmaceutical JSC No2 (HSTC:DP2) Headlines

No Headlines